Data for the MitraClip transcatheter edge-to-edge repair (TEER) device and the TriClip minimally invasive tricuspid heart valve repair device were presented at TVT: The Structural Heart Summit, the annual meeting from the Cardiovascular Research Foundation in Chicago.
The company said in a news release that the data on MitraClip and TriClip reinforce the capabilities of the structural heart solutions for both mitral and tricuspid regurgitation (MR and TR) across a range of patient groups managing leaky heart valves.
One-year results from Abbott’s MitraClip Expand study demonstrated the benefit of MitraClip in secondary MR patients both within the eligibility criteria for Abbott’s COAPT trial – which studied symptomatic heart failure patients with moderate-to-severe or severe secondary MR – and outside COAPT eligibility, including patients with moderate at baseline MR and patients with advanced heart failure.
Abbott said the study showed a significant MR reduction, improvements in the New York Heart Association (NYHA) class (a classification of functional limitations resulting from cardiac disease) and quality of life from baseline and comparable all-cause mortality and heart failure hospitalization rates.
The Triluminate and bRIGHT TriClip studies Abbot presented evaluated whether TR patients previously implanted with a pacemaker lead can benefit from the TriClip device and is the first report focusing on this group.
Patients with TR and a pacemaker lead across the tricuspid valve at 30 days showed a high rate of implant (98%) and acute procedural (91%) success, as well as a two-grade TR reduction in 64% of patients. Additionally, 69% of patients achieved NYHA Functional Class I/II, an improvement by 57% from baseline of 12%, with a marked 19-point improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) score (a self-assessment of symptoms, physical and social limitations, and quality of life in patients with heart failure).
“These latest data presented at TVT represent compelling evidence of progress in our mission to help people live better lives through better health,” SVP of Abbott’s structural heart business Michael Dale said in the release. “Our minimally invasive therapies for the treatment of heart valve disease are proof positive of our commitment to better serve physicians and improve the benefit of the devices we offer to the patients they treat.”
